Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABI-H0731 + peginterferon alfa-2a
- Development stage
- Unknown
- Lead developer
- Assembly Biosciences
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral, Subcutaneous
01
Overview
ABI-H0731 + peginterferon alfa-2a is an investigational combination therapy for chronic hepatitis B. **ABI-H0731** is a first-generation hepatitis B virus (HBV) core protein inhibitor; it acts by selectively inhibiting HBV DNA replication and suppressing covalently closed circular DNA (cccDNA) formation. Its mechanism is direct inhibition of the HBV core protein, preventing encapsidation of pregenomic RNA (pgRNA), disrupting nucleocapsids, and halting viral DNA synthesis and new cccDNA formation[1][5]. **Peginterferon alfa-2a** is a pegylated recombinant human interferon that activates the innate antiviral response by binding type I interferon receptors and inducing the JAK/STAT pathway, resulting in antiviral, immunomodulatory, and antiproliferative effects[2][6]. Peginterferon alfa-2a is approved for hepatitis B and C but has significant adverse effect profiles.[2][4] The combination aims to deliver complementary antiviral mechanisms and potentially higher rates of HBV functional cure than monotherapy.
- Other names
- peginterferon alfa-2apegylated interferon alpha-2a
02
Targets
HBc (Hepatitis B virus core protein)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on ABI-H0731 + peginterferon alfa-2a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABI-H0731 + peginterferon alfa-2a.